Inapill is developing 1st-in-class, oral small molecule therapeutics targeting immune cell metabolism (immunometabolism) for improved treatment of age-related chronic inflammatory and autoimmune disease. 

Recent honors:
-Creative Destruction Lab Advanced Therapies Program - 2025-26 cohort
-California Life Sciences (CLS) FAST Advisory program - Spring 2025 cohort

Inapill was co-founded by Greg Timblin, Josh Farahzad, and the therapeutics team @ General Inception (Palo Alto-based deep tech venture studio), and is a tenant at Bakar Bio Labs @ UC Berkeley. 

Inapill

Org chart

Teams

Offices

Inapill

Org chart

Teams

Offices

Related companies